Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report

Clicks: 245
ID: 271639
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 2 articles by views in cancer treatment and research communications

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
RET-rearrangement occurs in 1 to 2% of patients with non-small cell lung cancer (NSCLC), typically among non-smokers, and it is associated with an increased incidence of brain metastasis. While selpercatinib and pralsetinib are active for RET-rearranged NSCLC, the optimal standard frontline regimen …
Reference Key
s2021cancerfrontline Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Baby S;Khalil F;Tanvetyanon T;;
Journal cancer treatment and research communications
Year 2021
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/34166867
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:34166867 doi:10.1016/j.ctarc.2021.100423 sheon baby farah khalil tawee tanvetyanon

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.